Total 3Q 2025 net product revenue of $171.0 million, representing 63% year-over-year growthAUVELITY® 3Q 2025 net product sales of $136.1 million, ...

This case study explores how one pharmaceutical brand responded to a significant formulary loss, implementing seamless provider prior authorization strategies through CoverMyMeds to mitigate impact ...

Worth noting, CVS Caremark—the biggest PBM in the U.S.— announced in May that it would make Novo Nordisk’s rival drug Wegovy ...

This analysis reviews the history and current status of biosimilar regulation in the US, concluding that changing the FDA’s interchangeability standards—as proposed by some policy makers—is a ...

Tunstall: Medicaid cuts in HR 1 are likely to have an immediate impact. According to government estimates, these cuts could result in 17 million Americans losing their health coverage. Medicaid is a ...